Icosavax to Participate in in Upcoming Investor Conferences

Rhea-AI Summary

Icosavax, Inc. (Nasdaq: ICVX) is participating in key investor conferences to showcase its innovative vaccine development strategies. The company will present at the Guggenheim 4th Annual Immunology and Neurology Conference on November 15 at 9:00 am ET and engage in a Fireside Chat at the Jefferies London Healthcare Conference on November 17 at 6:20 am ET. Icosavax focuses on vaccines for serious respiratory diseases, leveraging its virus-like particle (VLP) technology. Webcasts of the presentations will be available on their website for 90 days post-event.

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the following investor conferences:

Guggenheim 4th Annual Immunology and Neurology Conference

• Icosavax will present on Tuesday, November 15 at 9:00 am ET
  

Jefferies London Healthcare Conference

• Icosavax will participate in a Fireside Chat on Thursday, November 17 at 6:20 am ET
  

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.icosavax.com. The webcast replays will be available following the conclusion of the presentations for approximately 90 days.

About Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), as well as programs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.

For more information, visit www.icosavax.com.

Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091

Investor Contact:
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
619.916.7620

FAQ

When will Icosavax present at the Guggenheim conference?

Icosavax will present on November 15 at 9:00 am ET during the Guggenheim 4th Annual Immunology and Neurology Conference.

What time is Icosavax's Fireside Chat at the Jefferies conference?

The Fireside Chat for Icosavax is scheduled for November 17 at 6:20 am ET at the Jefferies London Healthcare Conference.

Where can I access Icosavax's conference webcasts?

The live audio webcasts of Icosavax's presentations will be available on their website in the Investor Relations section for approximately 90 days after the events.

What is Icosavax focusing on in vaccine development?

Icosavax focuses on developing vaccines against life-threatening respiratory diseases using its innovative virus-like particle (VLP) platform technology.

What technology does Icosavax use for its vaccine development?

Icosavax utilizes an innovative virus-like particle (VLP) platform technology to create vaccines targeting various respiratory viruses.